Bioneeds India Private Limited - Due diligence report

A 360° intelligence report on Bioneeds: trust score, financial health, credit view, compliance, directors, growth and distress signals - gen…

2007-03-28 Bangalore, Karnataka Active Unlisted Active Compliant
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Bioneeds — 360° Intelligence Report

Generated from MCA filings & public records
60/100
Trust Score
Moderate

Bioneeds is assessed as Moderate with a Trust Score of 60/100. Bioneeds is an active private limited indian non-government company incorporated in 2007, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.

Report generated on 20 Nov 2026 from the latest processed filings. Bioneeds India Private Limited snapshot & full profile →

Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Caution

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
60/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
20/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
  • Moderate gearing (D/E 38%).
  • Profitable - internal accruals available.
  • Externally credit-rated (BBB).

Charges position: 1 open (26.42 cr) · 4 satisfied (15.84 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Canara Bank2 48.0 cr
Allahabad Bank Tumkur Branch1 48.0 cr
Axis Bank Limited2 48.0 cr
Compliance Score: 20/100 Caution Indicated
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2024 - filings overdue.
  • Flagged by authority: EPFO.
  • Litigation present in 1 court forum(s).
  • 1 auditor resignation(s) filed - latest: T N RAGHAVENDRA on 2021-04-26.
  • Delayed payments to MSME suppliers disclosed (69 disclosure(s)).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
NIRMAL ATMARAM BHATIA 01234567 Director 01/04/2018 6 yrs Approved
NITIN JAGANNATH DESHMUKH 01234567 Director 01/04/2018 6 yrs Approved
Pavagada Nanjaraja Gupta Naresh 01234567 Director 01/04/2018 6 yrs Approved
CHIRAG MAHESH SACHDEV 01234567 Director 01/04/2018 6 yrs Approved
PARAMESH KUMAR KIRAN 01234567 Director 01/04/2018 6 yrs Approved
Gajendra Narayanappa 01234567 Director 01/04/2018 6 yrs Approved
SHANKARAPPA NAGARAJA VINAYA BABU 01234567 Director 01/04/2018 6 yrs Approved
RAKESH BHARTIA 01234567 Director 01/04/2018 6 yrs Approved
VINAYAK PRABHAKAR SHENVI 01234567 Director 01/04/2018 6 yrs Approved
Gajendra Narayanappa 01234567 Director 01/04/2018 6 yrs Approved
  • 10 directors on the board.
  • No disqualified or deactivated DINs.
  • 3 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2026 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
VEEDA CLINICAL RESEARCH LIMITED
Subsidiaries
1
Group entities
1
Capital events
7 allotment(s) · 10 transfer(s)

Promoters hold a minority stake - exact percentages are part of the full report.

Group entityRelationship% held
AMTHERA LIFE SCIENCES PRIVATE LIMITED Subsidiary Company 74.00%
VEEDA CLINICAL RESEARCH LIMITED Holding Company 74.00%

Key managerial personnel: Pavagada Nanjaraja Gupta Naresh (CFO) · SHANKARAPPA NAGARAJA VINAYA BABU (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 55 · Distress 55
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 19+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Profit declined two years in a row.
Statutory filings appear overdue.
Compliance score is weak (20/100).
1 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 14.06 Lakh.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence42/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment62/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 26.42 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view62/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
07 Sep 2025
Director ceased
VINAYAK PRABHAKAR SHENVI
23 Aug 2025
Director appointed
VINAYAK PRABHAKAR SHENVI (Director)
12 Aug 2025
Director ceased
CHIRAG MAHESH SACHDEV
27 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Share transfer (FY 2024)
295385.00000000 shares to Veeda Clinical Research Limited
Latest balance sheet
Filed with ROC
21 Mar 2024
Director appointed
Gajendra Narayanappa (Company Secretary)
15 Mar 2024
Director appointed
Gajendra Narayanappa (Company Secretary)
29 Feb 2024
Director ceased
Prasanna Subramanya Bhat
31 Mar 2023
Share transfer (FY 2023)
595240.00000000 shares to Veeda Clinical Research Limited
Share transfer (FY 2023)
223666.00000000 shares to Veeda Clinical Research Limited
01 Aug 2022
Director appointed
NITIN JAGANNATH DESHMUKH (Director)
Director appointed
Pavagada Nanjaraja Gupta Naresh (CFO)
30 Jun 2022
Director ceased
PARAMESH KUMAR KIRAN
31 May 2022
Securities allotted
238096 Equity Shares - 10.00 cr raised
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
10 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of BBB from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2026 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 7 security allotment(s) - amounts available in the full report.
Approximately 141 employees on EPFO payroll records.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Petronash Engineering Services Private Limited U72200TN2010PTC076014 Sriperumbudur, Tamil Nadu, India
Rnd Optimizar Private Limited U74999TZ2017PTC029265 Coimbatore, Tamil Nadu, India
Praruh Technologies Limited L72900UP2019PLC123393 Noida, Uttar Pradesh, India
Enkingint L74200MP2011PLC025904 Indore, Madhya Pradesh, India
Kwick Soft Solutions U72200TN2005PLC055566 Egmore Nungambakkam, Tamil Nadu, India
Anlon Technology Solutions L74900MH2015PLC295795 Mumbai, Maharashtra, India
Khaitan L10000WB1936PLC008775 Kolkata, West Bengal, India
Capital Numbers L72200WB2012PLC183599 New Town, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Bioneeds before audits and certifications: compliance score 20/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Bioneeds: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 55/100, margin trends, ownership structure and peer set for Bioneeds - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 60/100, distress signals and MSME payment-delay disclosures - know whether Bioneeds pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Bioneeds - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Bioneeds an active company?

Bioneeds has MCA status “Active” with a compliance score of 20/100 (Caution Indicated).

Is Bioneeds financially healthy?

Bioneeds has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.

Should I do business with Bioneeds?

Its overall Trust Score is 60/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Bioneeds?

The ultimate holding entity is VEEDA CLINICAL RESEARCH LIMITED. 10 active director(s) are on record.

Does Bioneeds have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.

Is Bioneeds up to date with its ROC filings?

Last balance sheet is for Mar 2024 - filings overdue. Overall compliance score: 20/100 (Caution Indicated).

Is it risky to lend to Bioneeds?

Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.